Roth Capital set a $2.00 target price on Palatin Technologies, Inc. (NYSE:PTN) in a report released on Sunday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

PTN has been the subject of a number of other reports. Zacks Investment Research cut Palatin Technologies from a buy rating to a hold rating in a report on Saturday, October 7th. Canaccord Genuity set a $6.00 price target on Palatin Technologies and gave the stock a buy rating in a report on Sunday, September 10th.

Palatin Technologies (PTN) traded up 0.4730% on Friday, reaching $0.7435. The company had a trading volume of 624,469 shares. The company’s market capitalization is $133.12 million. The company’s 50-day moving average is $0.71 and its 200-day moving average is $0.48. Palatin Technologies has a 52-week low of $0.29 and a 52-week high of $0.90.

Palatin Technologies (NYSE:PTN) last released its quarterly earnings results on Monday, September 25th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.09. The company had revenue of $33.90 million during the quarter, compared to analyst estimates of $18.54 million. During the same period last year, the firm earned ($0.08) earnings per share. Equities analysts anticipate that Palatin Technologies will post ($0.35) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://theolympiareport.com/2017/10/30/palatin-technologies-inc-ptn-given-a-2-00-price-target-by-roth-capital-analysts.html.

Palatin Technologies Company Profile

Palatin Technologies, Inc is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.

Receive News & Ratings for Palatin Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.